Stability-indicating LC method for the estimation of bendamustine hydrochloride and its related impurities

Journal of Chromatographic Science

Volumn 52, Issue 7, 2014, Pages 573-583

  Kasa, Srinivasulu ^a,b   Reddy, M Raja Sekhar ^a   Kadaboina, Raja Sekhar ^a   Murki, Veerender ^a   Mulukutla, Venkata Suryanarayana ^b,c  

^a DR REDDY'S LABORATORIES LTD   (India)

^b OSMANIA UNIVERSITY   (India)

^c Mylan Laboratories Limited Anrich Industrial Estate   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CHLORMETHINE DERIVATIVE;

CHEMISTRY; DRUG CONTAMINATION; DRUG STABILITY; LIQUID CHROMATOGRAPHY; PH; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; LINEAR MODELS; NITROGEN MUSTARD COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84904302578     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bmt075     Document Type: Article

References (16)

1. Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., et al.; Bendamustine in patients with rituximabrefractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-Agent study; Journal of Clinical Oncology, (2008); 26(2): 204-210.
2. Teichert, J., Sohr, R., Baumann, F., Hennig, L., Merkle, K., Caca, K., et al.; Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma; Drug Metabolism and Disposition, (2005); 33(7): 984-992. (Pubitemid 41002781)
3. Gandhi, V.; Metabolism and mechanisms of action of bendamustine: Rationales for combination therapies; Seminars in Oncology, (2002); 29: 4-11. (Pubitemid 34857890)
4. Teichert, J., Baumann, F., Chao, Q., Franklin, C., Bailey, B., Hennig, L., et al.; Characterization of two phase I metabolites of Bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride; Cancer Chemotherapy and Pharmacology, (2007); 59(6): 759-770. (Pubitemid 46440598)
5. Rasschaert, M., Schrijvers, D., Van den Brande, J., Dyck, J., Bosmans, J., Merkle, K., et al.; A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours; British Journal of Cancer, (2007); 96(11): 1692-1698. (Pubitemid 46847200)
6. Gandhi, V., Burger, J.A.; Bendamustine in B cell malignancies: The new, 46-year old kid on the block; Clinical Cancer Research, (2009); 15(24): 7456-7461.
7. Lissitchkov, T., Arnaudov, G., Peytchev, D., Merkle, K.; Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy; Journal of Cancer Research and Clinical Oncology, (2006); 132(2), 99-104. (Pubitemid 41752051)
8. Pencheva, I., Bogomilova, A., Koseva, N., Obreshkova, D., Troev, K.; HPLC study on the stability of Bendamustine hydrochloride immobilized onto polyphosphoesters; Journal of Pharmaceutical and Biomedical Analysis, (2008); 48(4): 1143-1150.
9. Annapurna, M.M., Pavani, S., Anusha, S., Mahanti, H., Venkatesh, B.; New analytical methods for the determination of Bendamustine hydrochloride: An anti-neoplastic drug; Journal of Chemical and Pharmaceutical Research, (2012); 4(3): 1696-1701.
10. Dubbelman, A.C., Tibben, M., Rosing, H., Gebretensae, A., Nan, L., Gorman, S.H., et al.; Development and validation of LC-MS/MS assays for the quantification of Bendamustine and its metabolites in human plasma and urine; Journal of Chromatography B, (2012); 893-894: 92-100.
11. International Conference on Harmonization (ICH). Q1A(R2), Stability testing of new drug substances and products. Geneva, Switzerland, (2000).
12. ICH. Q1A (R2), Stability testing of new drug substances and products. Geneva, Switzerland, (2003
13. United States Pharmacopoeia (USP), 31st edition. United States Pharmacopeial Convention, Rockville, MD, (2008).
14. Carstensen, J.T., Rhodes, C.T. (eds). Drug stability principles and practices, 3rd edition, Marcel Dekker, New York, NY, (2000).
15. Bakshi, M., Singh, S.; Development of validated stability-indicating assay methods-Critical review; Journal of Pharmaceutical and Biomedical Analysis, (2002); 28: 1011-1040. (Pubitemid 34607392)
16. ICH. Q2 (R1), Validation of analytical procedures: Text and methodology, Geneva, Switzerland, (2005).